Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | MRGPRX4 | Q96LA9 | 3/20 | 0.42 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
| ▸ | ECE1 | P42892 | 1/20 | 0.38 |
| ▸ | TRPM8 | Q7Z2W7 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29892650 | 0.88 | KDM4E (0.48) | KDM4EALOX15TSHRACMSDTDP1 | |
| SCHEMBL2349945 | 0.88 | KDM4E (0.48) | KDM4EALOX15TSHRACMSDTDP1 | |
| SCHEMBL30538868 | 0.88 | KDM4E (0.55) | KDM4EALOX15TSHRACMSDTDP1 | |
| SCHEMBL2310414 | 0.88 | KDM4E (0.55) | KDM4EALOX15TSHRACMSDTDP1 | |
| SCHEMBL15865623 | 0.87 | KDM4E (0.47) | KDM4EALOX15TSHRACMSDTDP1 | |
| SCHEMBL30960193 | 0.87 | KDM4E (0.47) | KDM4EALOX15TSHRACMSDTDP1 | |
| SCHEMBL22451834 | 0.82 | KDM4E (0.57) | KDM4EALOX15TSHRACMSDTDP1 | |
| SCHEMBL12453251 | 0.82 | KDM4E (0.46) | KDM4EALOX15TSHRACMSDTDP1 | |
| SCHEMBL12453810 | 0.82 | KDM4E (0.48) | KDM4EALOX15TSHRACMSDTDP1 | |
| SCHEMBL1698577 | 0.81 | KDM4E (0.52) | KDM4EALOX15TSHRACMSDTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8772446-B2 | Bifunctional chelating agents | NORDION (CANADA) INC. (CA) | 2014-07-08 | — | — | US | disclosed |
| US-20110313130-A1 | BIFUNCTIONAL CHELATING AGENTS | NORDION (CANADA) INC. | 2011-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110313130-A1 | BIFUNCTIONAL CHELATING AGENTS | FCGRT, C1QBP, H1-2 | KDM4E 3809/4885ALOX15 4305/4885TSHR 682/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.